Home > Resources > Whitepapers > The challenges of scaling up pharmaceutical manufacturing

The challenges of scaling up pharmaceutical manufacturing

February 18, 2019

Maintaining the integrity of a drug during a pharmaceutical manufacturing scale-up isn’t always an easy feat, but it’s essential for producers who wish to grow their operation while ensuring high standards and legal compliance.

Spotlight

CODAC Behavioral Health Services, Inc.

CODAC is one of Arizona’s oldest and most respected community providers of specialty care for mental illness, addiction and trauma. What began as a grassroots drug abuse prevention program has grown into a multi-faceted organization that provides services across the entire spectrum of behavioral health care. Through 11 service locations and over 400 staff and volunteers, CODAC now serves more than 15,000 individuals and families each year. CODAC is a nonprofit 501(C)(3) organization. We are here to help you meet your mental health, substance abuse, trauma, primary care and general wellness goals. A variety of treatment professionals will partner with you to develop a plan and take positive steps toward a healthy, productive, caring life in recovery from a mental illness, substance use disorder and/or trauma.

OTHER WHITEPAPERS

A Futuristic Approach to Message Testing for Pharma Companies

whitePaper | March 10, 2023

In the last decade, the pharma industry has gone through significant changes in how it messages to physicians, patients and payers. The processes and tools that pharma brands use to DEVELOP and DELIVER messages have been disrupted by new technologies.

The Age of Coaching

whitePaper | March 4, 2022

The pandemic has been healthcare and the pharmaceutical industry’s meteor moment established eco-systems have been wiped out andsales force routines have been scorched from the face of the earth.

Learning from the COVID-19 Policy Response

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

Four best practices for single-use supply chain success

whitePaper | February 16, 2023

Flexible and cost-effective, single-use technologies offer biopharmaceutical companies a way to transform their biologics production and meet the growing demand for these life-changing therapies.

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

The challenges of scaling up pharmaceutical manufacturing